Please login to the form below

Not currently logged in
Email:
Password:

Bioequivalence study triggers milestone payment for Eurand

Eurand completes a bioequivalence study with GlaxoSmithKline regarding an undisclosed GSK compound

Eurand, an Italian/ US-based specialty pharmaceutical company, has successfully completed a bioequivalence study with GlaxoSmithKline (GSK), regarding an undisclosed GSK compound. 

UK-headquartered GSK will make a payment of USD 1.5m to Eurand in recognition of the milestone.

The new formulation, which uses Eurand's Microcaps and AdvaTab technologies, is designed to dissolve quickly in the mouth to reduce the bitter taste of some medications. Eurand could potentially receive milestone payments from GSK totalling up to USD 42m for the development of the product. GSK expects to file an NDA in the near future.

Under the agreement, Eurand will manufacture the product for GSK and receive royalty revenues when the product receives NDA approval from the FDA.

Gearoid Faherty, CEO of Eurand, said: "We are delighted with the results of the bio-study and are looking forward to GSK submitting their NDA."

4th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics